Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic collaboration with Lilly ExploR&D expands therapeutic approach to novel metabolic aging targetsProgression of preclinical next-generation APJ agonists for obesity RICHMOND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided business updates and reported its first quarter 2025 financial results. "The first quarter of 2025 was marke

Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships with Novartis and Lilly to discover and develop novel therapies for conditions driven by metabolic aging RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided financial results for the full year ended December 31, 2024 and business updates for the fourth quarter ended Decembe

STOCKHOLM, March 17, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases with a high medical need. Multiple System Atrophy (MSA) is a rapidly progressive and fatal rare disease affecting the central and autonomic nervous systems. MSA is characterized by pathological alpha-synuclein aggregation, that causes gradual damage to nerve cells in the brain. This affects balance, movement and the autonomic nervous system, which

STOCKHOLM, Sweden, March 3, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ:BIOA) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia has declined the approval of lecanemab (generic name) as a treatment for early Alzheimer's disease (AD) (mild cognitive impairment due to AD and mild AD dementia). Eisai remains committed to ensuring eligible Australians with early Alzheimer's disease can access lecanemab and is exploring options to achieve this, including potentially seeking review by the Administrative Review Tribunal. In October 2024, the TGA made the decision not to register lecanemab in Australia for the treatment of patients

RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in one-on-one meetings at TD Cowen's 45th Annual Health Care Conference. TD Cowen's 45th Annual Health Care Conference is taking place on March 3–5, 2025, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and innovative panel discussions, moderated by members of the TD Cowen research team, that focus on various aspects of the health

Advancement of next-generation APJ agonists with discontinuation of azelaprag Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025 Expansion of discovery efforts based on insights from BioAge's platform, including a target identification collaboration with Novartis and a newly announced antibody therapeutics development collaboration with Lilly ExploR&D RICHMOND, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced compan

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging Novartis to pay up to $20M comprising upfront payments and research funding; BioAge may receive up to $530M in future long-term research, development, and commercial milestones RICHMOND, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced a multi-year research collaboration with Novartis. The collaboratio

Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share updated plans for azelaprag in Q1 2025 In parallel to evaluating azelaprag, Company will continue to advance earlier platform-derived programs, including IND submission for CNS penetrant NLRP3 inhibitor anticipated in the second half of 2025 RICHMOND, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today an

RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Goldman Sachs Second Annual "Year-Ahead" Catalyst Clinic on Thursday, December 19, 2024, 11–12 PM EST. To access the live webcast of the virtual presentation, register here. Replays of the webcast will be available in the investor section of the Company's website at https://ir.bioagelabs.com, and will be archived for 30 days following the presentation. About BioAge Labs, Inc.BioAge is a

RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: Piper Sandler 36th Annual Healthcare Conference (New York, December 3-5, 2024): Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a company presentation on December 3, 2024 from 1:30 PM to 1:55 PM EST, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here.Citi 2024 Glo

4/A - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4/A - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

William Blair initiated coverage of BioAge Labs with a rating of Mkt Perform

Morgan Stanley downgraded BioAge Labs from Overweight to Underweight and set a new price target of $5.00 from $40.00 previously

Jefferies downgraded BioAge Labs from Buy to Hold and set a new price target of $7.00 from $42.00 previously

Citigroup downgraded BioAge Labs from Buy to Neutral and set a new price target of $7.00 from $45.00 previously

Citigroup initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $45.00

Jefferies initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $42.00

Morgan Stanley initiated coverage of BioAge Labs with a rating of Overweight and set a new price target of $40.00

4/A - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

10-Q - BioAge Labs, Inc. (0001709941) (Filer)

8-K - BioAge Labs, Inc. (0001709941) (Filer)

DEFA14A - BioAge Labs, Inc. (0001709941) (Filer)

DEF 14A - BioAge Labs, Inc. (0001709941) (Filer)

S-8 - BioAge Labs, Inc. (0001709941) (Filer)

10-K - BioAge Labs, Inc. (0001709941) (Filer)

8-K - BioAge Labs, Inc. (0001709941) (Filer)

SCHEDULE 13G/A - BioAge Labs, Inc. (0001709941) (Subject)

SCHEDULE 13G - BioAge Labs, Inc. (0001709941) (Subject)

10-Q - BioAge Labs, Inc. (0001709941) (Filer)

SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

SC 13D - BioAge Labs, Inc. (0001709941) (Subject)

SC 13D - BioAge Labs, Inc. (0001709941) (Subject)